Preoperative Preparation With Selective versus Nonselective Alpha-Adrenoceptor Blockade for Pheochromocytomas and Paragangliomas: A Systematic Review and Updated Meta-Analysis.

Endocr PractMay 11, 2026 (epub)
Clinical ResearchEndocrinologyGeneral Surgery

Zhixiang Pan, Chao Wang, Quanheng Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of nonselective alpha-blockers (NAB) versus selective alpha-blockers (SAB) for preoperative preparation in patients with pheochromocytomas and paragangliomas (PPGL). Involving 2293 patients across 20 studies, NAB significantly reduced the risk of intraoperative hypertensive crisis (OR: 0.33) and maximum systolic blood pressure (MD: -12.85 mmHg) compared to SAB.

Key findings

  • NAB significantly reduced the risk of intraoperative hypertensive crisis (OR: 0.33, P < .001).
  • Maximum intraoperative systolic blood pressure was lower with NAB (MD: -12.85 mmHg, P < .001).
  • Intraoperative vasopressor use was less frequent in the NAB group (OR: 0.60, P = .02).
  • NAB maintained a higher minimum systolic blood pressure (MD: 2.02 mmHg, P = .008).

Why it matters

Understanding the comparative effectiveness of NAB and SAB is essential for optimizing preoperative management in patients with PPGL, as it can significantly impact intraoperative hemodynamic stability and patient outcomes.

Source

PubMed · PMID 42119970

Published in Endocr Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.